Literature DB >> 2799488

[Phagotherapy of postoperative suppurative-inflammatory complications in patients with neoplasms].

V A Kochetkova, A S Mamontov, R L Moskovtseva, E I Erastova, E I Trofimov, M I Popov, S K Dzhubalieva.   

Abstract

The authors assess the efficacy of phage therapy ofsuppurative and inflammatory complications in oncological patients. A clinical and laboratory analysis has involved 131 patients whose etiotropic therapy consisted of bacteriophages (65 patients) and antibiotics (66). Medicinal phages, manufactured by the Tbilisi Research Institute for Vaccines and Sera, have been administered according to 3 schemes: (1) parallel with antibiotics, (2) after long ineffective antibiotic therapy, (3) phages alone starting from the onset of the purulent complication. The preparations have been prescribed with due consideration for the isolated microflora sensitivity. Incorporation of phages in combined therapy of infectious complications has yielded positive results in 81.5% of cases, whereas antibiotics have proved effective in but 60.6%. The efficacy of phage therapy depends on the type of pyoinflammatory complications (the results are the best in the management of wound infections), the microflora pattern of the purulent foci (phages are the most effective with a corresponding monoinfection), characteristics of the therapeutic phages proper (Pseudomonas aeruginosa phage is characterized by the highest therapeutic activity, as compared to staphylococcal and other phages).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2799488

Source DB:  PubMed          Journal:  Sov Med        ISSN: 0038-5077


  10 in total

Review 1.  Bacteriophage therapy.

Authors:  A Sulakvelidze; Z Alavidze; J G Morris
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

2.  Phage treatment of human infections.

Authors:  Stephen T Abedon; Sarah J Kuhl; Bob G Blasdel; Elizabeth Martin Kutter
Journal:  Bacteriophage       Date:  2011-03

3.  Co-therapy using lytic bacteriophage and linezolid: effective treatment in eliminating methicillin resistant Staphylococcus aureus (MRSA) from diabetic foot infections.

Authors:  Sanjay Chhibber; Tarsem Kaur
Journal:  PLoS One       Date:  2013-02-13       Impact factor: 3.240

Review 4.  Facing antibiotic resistance: Staphylococcus aureus phages as a medical tool.

Authors:  Zuzanna Kaźmierczak; Andrzej Górski; Krystyna Dąbrowska
Journal:  Viruses       Date:  2014-07-01       Impact factor: 5.048

5.  Proteomic Characterization of Lytic Bacteriophages of Staphylococcus aureus Isolated from Sewage Affluent of India.

Authors:  Kamalpreet Kaur Sangha; B V Sunil Kumar; Ravi Kant Agrawal; Dipak Deka; Ramneek Verma
Journal:  Int Sch Res Notices       Date:  2014-09-14

6.  Synergistic Antimicrobial Interaction between Honey and Phage against Escherichia coli Biofilms.

Authors:  Ana Oliveira; Henrique G Ribeiro; Ana C Silva; Maria D Silva; Jessica C Sousa; Célia F Rodrigues; Luís D R Melo; Ana F Henriques; Sanna Sillankorva
Journal:  Front Microbiol       Date:  2017-12-08       Impact factor: 5.640

Review 7.  Applications of Bacteriophages in the Treatment of Localized Infections in Humans.

Authors:  Vera V Morozova; Valentin V Vlassov; Nina V Tikunova
Journal:  Front Microbiol       Date:  2018-08-02       Impact factor: 5.640

Review 8.  Bacteriophages Against Pathogenic Bacteria and Possibilities for Future Application in Africa.

Authors:  Tesfaye Kassa
Journal:  Infect Drug Resist       Date:  2021-01-06       Impact factor: 4.003

9.  Isolation, Characterization and in vitro Evaluation of Specific Bacteriophages Targeting Extensive Drug Resistance Strains of Pseudomonas aeruginosa Isolated from Septic Burn Wounds.

Authors:  Seyed Mahmoud Amin Marashi; Farhad Nikkhahi; Dariush Hamedi; Gholamhassan Shahbazi
Journal:  Infect Chemother       Date:  2022-03

Review 10.  Developing New Antimicrobial Therapies: Are Synergistic Combinations of Plant Extracts/Compounds with Conventional Antibiotics the Solution?

Authors:  Matthew J Cheesman; Aishwarya Ilanko; Baxter Blonk; Ian E Cock
Journal:  Pharmacogn Rev       Date:  2017 Jul-Dec
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.